Table 1 Inclusion and exclusion criteria
Inclusion criteria | |
1 | Human, in vivo studies |
2 | Any language |
3 | Differentiation between benign and malignant lesions in any organ |
4 | ADC measurements used to differentiate benign from malignant lesions |
5 | It was possible to classify ADC measurements into a group of benign and a group of malignant lesions |
6 | Histological examination used as reference standard |
7 | Diffusion-weighted MRI with ADC measurements performed prior to any treatment |
8 | Absolute outcome measures (mean ADCs) can be obtained from article |
9 | Total sample size of at least 20 lesions |
10 | MR ≥ 1 Tesla |
11 | All ages |
Exclusion criteria | |
1 | Therapeutic or prognostic studies |
2 | Reviews, meta-analyses, editorials, case reports |
3 | Studies that focus solely on ADC values of (pathologic) lymph nodes or vertebral fractures |